LEGAL STATUS — verified 10 Aug 2026: DEA notices of intent to temporarily Schedule I concentrated 7-OH (above threshold) and related analogues are published; no temporary scheduling order located yet — recheck the Federal Register before counseling.

Dependence & withdrawal

A provisional course—not a stopwatch.

There is no validated prospective 7-OH withdrawal time-course study. The bands below help people plan; they are not a warranty, home-detox recipe, or fixed buprenorphine clock.

Synthesis from published cases, early series, opioid pharmacology, and practice-based experience. Product composition, dose, interval, duration, coexposures, illness, and treatment can move the timeline substantially.
Evidence-banded provisional 7-OH withdrawal timeline
Evidence-banded provisional timeline. Numbers are planning aids, not guarantees.

Dependence phenotype

Symptom domains

Opioid-like: yawning, lacrimation/rhinorrhea, piloerection, chills, sweating, restlessness, myalgias, abdominal cramping, nausea, vomiting, diarrhea, tachycardia, hypertension, insomnia, craving.

Affective/cognitive: anxiety, dysphoria, irritability, poor concentration, fatigue, low mood—often outlasting the most obvious autonomic/GI phase.

Mixed/product-related: tremor, stimulation, severe insomnia, or symptoms from nicotine, stimulants, alcohol, benzodiazepines, gabapentinoids, or undeclared compounds.

Provisional timeline

Time from last doseBest-available expectationConfidence
0–8 hHeavy users may notice interdose withdrawal; others may still feel relatively well.Practice-based / emerging
8–24 hClinically significant withdrawal often becomes clearer.Emerging
16–36 hProvisional peak window for many short-acting presentations—not universal.Provisional
Days 2–3Often the roughest overall period for autonomic, GI, sleep, anxiety, and craving.Emerging
Days 3–5Vomiting/diarrhea, chills, sweating, and pain often begin to ease; sleep/mood/craving may remain.Practice-based / indirect
Day 5–2+ weeksAcute physical symptoms usually fade; insomnia, low mood, fatigue, and craving can persist.Practice-based / analogy

Why COWS can under-read

COWS was not designed around 7-OH products or mixed alkaloids. It can underweight severe insomnia, dysphoria, disproportionate abdominal distress, mixed stimulant/sedative symptoms, and fluctuating state after frequent redosing.

Fentanyl substitution risk

Losing retail access without a treatment plan can drive stockpiling or substitution with counterfeit pills or street opioids. That is a foreseeable failure mode worth preventing—not a measured epidemic curve. See treatment and crisis.

Patients & families · Clinicians · Assessment template